Cardiac replacement therapy is a treatment option for patients with advanced heart failure refractory to guideline-directed medical therapy or those presenting with cardiogenic shock. In the past, the term cardiac replacement therapy was limited only to cardiac transplantation. Indeed, nowadays, the term also refers to long-term implantable left ventricular assist devices (LVADs), and total artificial heart (TAH). In the future, it could also refer to xeno-transplantation and cardiac genic therapy.
Currently, heart transplantation is the gold standard therapy but the number of patients with end-stage heart failure is increasing, and they are more complex (advanced age, often supported with mechanical circulatory support, large sensitization to HLA), whereas the number of donor organs remains stable and with many limited factors. We would focus on current strategies for increasing the pool of donors and strategies to increase the survival of heart failure recipients.
In recent years, the ventricular assist device reported some technological innovations with consequent reduction of adverse events and improvement of mid and long-term survival rates. We would focus on the optimization of VAD support mainly as a bridge to destination therapy.
We will also be interested in new frontiers of research such as total artificial heart, xenotransplantation, or cardiac genic therapy.
This research topic is open to all articles about every aspect of cardiac replacement therapy.
Keywords:
Heart transplantation, Ventricular Assist Device, Total artificial heart, advanced heart failure, cardiogenic shock, mechanical circulatory support
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Cardiac replacement therapy is a treatment option for patients with advanced heart failure refractory to guideline-directed medical therapy or those presenting with cardiogenic shock. In the past, the term cardiac replacement therapy was limited only to cardiac transplantation. Indeed, nowadays, the term also refers to long-term implantable left ventricular assist devices (LVADs), and total artificial heart (TAH). In the future, it could also refer to xeno-transplantation and cardiac genic therapy.
Currently, heart transplantation is the gold standard therapy but the number of patients with end-stage heart failure is increasing, and they are more complex (advanced age, often supported with mechanical circulatory support, large sensitization to HLA), whereas the number of donor organs remains stable and with many limited factors. We would focus on current strategies for increasing the pool of donors and strategies to increase the survival of heart failure recipients.
In recent years, the ventricular assist device reported some technological innovations with consequent reduction of adverse events and improvement of mid and long-term survival rates. We would focus on the optimization of VAD support mainly as a bridge to destination therapy.
We will also be interested in new frontiers of research such as total artificial heart, xenotransplantation, or cardiac genic therapy.
This research topic is open to all articles about every aspect of cardiac replacement therapy.
Keywords:
Heart transplantation, Ventricular Assist Device, Total artificial heart, advanced heart failure, cardiogenic shock, mechanical circulatory support
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.